Shattuck Labs Inc at Needham Healthcare Conference (Virtual) Transcript
My name is Gil Blum and I'm a Senior Biotech Analyst here at Needham & Company, covering immuno-oncology and the gene therapy subsectors. It is my pleasure to have with me today Shattuck's management team, including Taylor Schreiber, CEO; and Andrew Neill, the Chief Financial Officer. As a reminder, any viewers who are watching through our conference portal are able to submit questions via the Ask A Question box, below the video feed window.
So to kind of start things off, maybe it's worth reminding our audience of Shattuck's key technology, which is these agonist redirected checkpoints, which are dual-targeting molecules with unique structural properties. So maybe describe one of these for us and how it's different compared to existing therapeutics, let's say, small molecules and antibodies.
Sure. Well, Gil, thank you for having us, and thanks to Needham. It's our pleasure to present at the fireside chat with you today. And so to start off
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |